Grignani, G., Palmerini, E., Ferraresi, V., D’Ambrosio, L., Bertulli, R., Asaftei, S.D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., Capozzi, F., Biagini, R., Gambarotti, M., Fagioli, F., Casali, P.G., Picci, P., Ferrari, S. and Aglietta, M. (2015) Sorafenib and Everolimus for Patients with Unresectable High-Grade Osteosarcoma Progressing after Standard Treatment: A Non-Randomised Phase 2 Clinical Trial. The Lancet Oncology, 16, 98-107.
https://doi.org/10.1016/S1470-2045(14)71136-2

has been cited by the following article:

• TITLE: Cyclophosphamide and Etoposide as a Salvage Treatment in Metastatic Osteosarcoma Patients

  AUTHORS: Fatma MF Akl, Mohamed Farouk Akl

  KEYWORDS: Cyclophosphamide, Etoposide, Metastatic Osteosarcoma, Salvage Chemotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.7, July 9, 2018

  ABSTRACT: Background and Objective: Osteosarcoma is a rare bone cancer with approximately 30% - 35% of patients who will relapse either systemically or locally, with the lung being the commonest site of relapse. The objective of this trial was to evaluate the efficacy of cyclophosphamide and etoposide, in treatment of metastatic osteosarcoma patients progressed after one or more chemotherapy lines, with the progression free survival and treatment response as the primary endpoints, while the secondary endpoints were overall survival and treatment toxicity. Patients and Methods: Twenty seven metastatic osteosarcoma patients were enrolled into this trial and received cyclophosphamide and etoposide chemotherapy. Cyclophosphamide was given at a dose of 500 mg/m2 per day, I.V for 5 days and etoposide (100 mg/m2 per day I.V for 5 days). Response was assessed after 3 cycles according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Chemotherapy Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Results: The median overall survival time and progression-free survival were 12 months and 8 months, respectively. Four patients (14.8%) achieved partial response; 14 patients (51.9%) had stationary disease (SD); and 9 (33.3%) expressed tumor progression. Hematologic toxicity was the main toxicity. None of the patients had G4 or life threatening toxicities. Conclusion: The combination of cyclophosphamide and etoposide represents an efficient and tolerable treatment option for patients with metastatic osteosarcoma.